| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |